Skip to main content

Published locations for Bevacizumab Doubles Risk of GI Adverse Events in Key Ovarian Cancer Trial

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Bevacizumab Doubles Risk of GI Adverse Events in Key Ovarian Cancer Trial

User login

  • Reset your password
  • /content/bevacizumab-doubles-risk-gi-adverse-events-key-ovarian-cancer-trial
  • /internalmedicinenews/article/32592/oncology/bevacizumab-doubles-risk-gi-adverse-events-key-ovarian
  • /oncologypractice/article/32592/oncology/bevacizumab-doubles-risk-gi-adverse-events-key-ovarian
  • /hematology-oncology/article/32592/oncology/bevacizumab-doubles-risk-gi-adverse-events-key-ovarian
  • /internalmedicine/article/32592/oncology/bevacizumab-doubles-risk-gi-adverse-events-key-ovarian